JAK3 | bioCADDIE Data Discovery Index
Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Displaying 100 of 559 results for "JAK3"
i
  1. JAK3 with covalent inhibitor PF-06651600 PDB

    ID: PDB:5TOZ

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  2. Crystal structure of JAK3 kinase domain in complex with an indazole substituted pyrrolopyrazine PDB

    ID: PDB:3ZC6

    Description: TYROSINE-PROTEIN KINASE JAK3 (E.C.2.7.10.2, 2.7.1.112)

  3. JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-oxo-2-piperidin-1-yl-ethyl)-amide PDB

    ID: PDB:4HVI

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  4. JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-hydroxy-1,2-dimethyl-propyl)-amide PDB

    ID: PDB:4HVG

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  5. Crystal structure of JAK3 kinase domain in complex with a pyrrolopyridazine carboxamide inhibitor PDB

    ID: PDB:4RIO

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  6. JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl PDB

    ID: PDB:4HVH

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  7. JAK3 kinase domain in complex with 2-Cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide PDB

    ID: PDB:4HVD

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  8. Crystal structure of JAK3 complexed with a potent ATP site inhibitor showing high selectivity within the Janus kinase family PDB

    ID: PDB:3PJC

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  9. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease PDB

    ID: PDB:4YTI

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  10. Jak3 with covalent inhibitor 7 PDB

    ID: PDB:5TTU

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  11. Crystal structure of JAK3 in complex with Compound 4 (FM381) PDB

    ID: PDB:5LWM

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  12. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases PDB

    ID: PDB:4YTH

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  13. Crystal structure of JAK3 in complex with Compound 5 (FM409) PDB

    ID: PDB:5LWN

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  14. JAK3 kinase domain in complex with 2-Phenoxy-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-cyclopropyl-ethyl)-amide PDB

    ID: PDB:4I6Q

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  15. Jak3 with covalent inhibitor 4 PDB

    ID: PDB:5TTS

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  16. Jak3 with covalent inhibitor 6 PDB

    ID: PDB:5TTV

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  17. Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6 PDB

    ID: PDB:3LXK

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  18. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue PDB

    ID: PDB:1YVJ

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.1.112)

  19. Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6 PDB

    ID: PDB:3LXL

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  20. CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR PDB

    ID: PDB:5VO6

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  21. Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6 PDB

    ID: PDB:3LXN

    Description: Non-receptor tyrosine-protein kinase TYK2 (E.C.2.7.10.2)

  22. JAK3 kinase domain in complex with 1-[(3S)-1-isobutylsulfonyl-3-piperidyl]-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)urea PDB

    ID: PDB:4QT1

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  23. JAK3_RAT UniProt:Swiss-Prot

    ID: Q63272

    Description: Tyrosine-protein kinase JAK3 FERM SH2; atypical Protein...

  24. Crystal Structure of JAK3 Kinase Domain in Complex with a Pyrrolopyrazine-2-phenyl Ether Inhibitor PDB

    ID: PDB:3ZEP

    Description: TYROSINE-PROTEIN KINASE JAK3 (E.C.2.7.10.2, 2.7.1.112)

  25. Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6 PDB

    ID: PDB:3LXP

    Description: Non-receptor tyrosine-protein kinase TYK2 (E.C.2.7.10.2)

  26. Crystal Structure of the Jak3 Kinase Domain Covalently Bound to N-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-... PDB

    ID: PDB:4Z16

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  27. JAK3 in complex with a covalent EGFR inhibitor PDB

    ID: PDB:4V0G

    Description: TYROSINE-PROTEIN KINASE JAK3 (E.C.2.7.10.2)

  28. Inhibition of activation of Sez-4 cell line with IL-2 by Jak kinase inhibitors. BioProject

    ID: PRJNA101903

    Keywords: Transcriptome or Gene expression

    Access Type: download

  29. Effect of a JAK inhibitor on gene expression of HUT78 cell line ArrayExpress

    ID: E-GEOD-68562

    Description: increasing evidence that activating mutations in JAK genes and deregulated JAK/STAT signaling are important mechanisms involved in multiple B and T cell malignancies, including CTCL. Therefore, in this study we focused on studying the mutational status of JAK1, JAK2 and JAK3 genes in a series of human CTCL...

  30. Effect of JAK1/3 blockade on IL2 response in NK cells BioProject

    ID: PRJNA329657

    Keywords: Transcriptome or Gene expression

    Access Type: download

  31. Effect of JAK1/3 blockade on IL2 response in NK cells ArrayExpress

    ID: E-GEOD-84562

    Description: IL2 signals are transmitted through JAK1 and JAK3, but the transcriptomic consequences of each to the overall response is unclear. Here we analyzed the relative contribution of...

  32. Effect of a JAK inhibitor on gene expression of HUT78 cell line BioProject

    ID: PRJNA283116

    Keywords: Transcriptome or Gene expression

    Access Type: download

  33. Crystal structure of Jak3 complexed to N-[3-(6-Phenylamino-pyrazin-2-yl)-3H-benzoimidazol-5-yl]-acrylamide PDB

    ID: PDB:4QPS

    Description: Tyrosine-protein kinase JAK3 (E.C.2.7.10.2)

  34. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D... ArrayExpress

    ID: E-GEOD-35907

    Description: ernal tandem duplication (ITD) of the fms-related tyrosine kinase-3 (FLT3) gene occurs in 30% acute myeloid leukemias (AML) and confers a poor pro...

  35. Homo sapiens : Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9 Enhanced Gene Replaceme BioProject

    ID: PRJNA278158

    Keywords: genome sequencing

    Access Type: download

    dataset.description: Mutations of the Janus family kinase JAK3 gene cause severe combined immunodeficiency (SCID). JAK3
  36. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases PDB

    ID: PDB:4YTF

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  37. Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease PDB

    ID: PDB:4YTC

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  38. Transcription profiling of human Sez-4 cell line starved of IL2 for 16h, followed by addition of IL-2 activation and or JAK inhibition ArrayExpress

    ID: E-GEOD-8687

    Description: -regulated <40 genes. All three cytokines induced tyrosine phosphorylation of Jak1 and Jak3. However, only IL-2 and IL-15 strongly activated STAT5, PI3K/Akt, and MEK/ERK signaling pathways. In contrast, IL-21 selectively activated STAT3. Whereas all three cytokines protected CTCL cells from apoptosis, only IL-2 and IL-15 promoted their proliferation. The effects of the cytokine stimulation were Jak3- and Jak1-kinase dependent. These findings document the vastly different impact of IL-2 and IL-15 vs. IL-21 on malignant CD4+ T cells. They also suggest two n...

  39. Methylation data and effect of JAK3 inhibition on human MO-to-DC and MO-to-MAC differentiation BioProject

    ID: PRJNA305748

    Keywords: Epigenomics

    Access Type: download

  40. Homo sapiens : Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9 Enhanced Gene Replaceme BioProject

    ID: PRJNA278160

    Keywords: genome sequencing

    Access Type: download

    dataset.description: Mutations of the Janus family kinase JAK3 gene cause severe combined immunodeficiency (SCID). JAK3
  41. Expression data from NKYS transfected with siRNAs or plasmids BioProject

    ID: PRJNA305040

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: The siRNA transfection includes JAK3 and EZH2 siRNAs. The plasmid transfection includes EZH2 WT and its mutants. We used gene expression data from JAK3
  42. Polynucleobacter yangtzensis strain:MWH-JaK3 : Polynucleobacter MWH-JaK3 Genome sequencing BioProject

    ID: PRJNA277963

    Keywords: Genome sequencing and assembly

    Access Type: download

  43. Gene expression of Kit225 cells upon NC1153 treatment BioProject

    ID: PRJNA117747

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: NC1153 was shown to inhibit JAK3 tyrosine kinase. Lymphocytes survival depends on the integrity of STAT5, the primary dow...
  44. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker BioProject

    ID: PRJNA274578

    Keywords: Variation

    Access Type: download

  45. Methylation data and effect of JAK3 inhibition on human MO-to-DC and MO-to-MAC differentiation ArrayExpress

    ID: E-GEOD-75937

    Description: ts on the methylation profiles of DCs and MACs of JAK3 inhibitor PF-956980 The methylation profiles of bisulfite-modified DNA of human CD14+ monocytes were compared with derived dendritic cells (DCs), macrophages (MACs) following GM-CSF/IL-4 and GM-CSF incubation, and DC and MAC samples incubated with JAK3 inhibitor PF-956980 using the Infinium HumanMethylation450 BeadChips (...

  46. Expression data from NKYS transfected with siRNAs or plasmids ArrayExpress

    ID: E-GEOD-75680

    Description: The siRNA transfection includes JAK3 and EZH2 siRNAs. The plasmid transfection includes EZH2 WT and its mutants. We used gene expression data from JAK3

  47. Cytoscan HD arrays data for Nodal marginal zone lymphoma (NMZL) BioProject

    ID: PRJNA281882

    Keywords: Variation

    Access Type: download

    dataset.description: 14) translocations; and ii) recurrently harbored +3 (14%), +12 (14%) and preferential usage of the IGHV4-34 gene (17%). WES (HiSeq 2500, Illumina; mean coverage per sample: 38x-114x) and high resolution SNP array (Cytoscan HD, Affymetrix) of tumor/normal DNA pairs from 18 discovery NMZL identified 557 non-synonymous somatic mutations (average: 30.8/case) affecting 504 genes and 51 copy number abnormalities (CNA) (average: 3.2/case). To further characterize mutation recurrence, the 504 discovered genes were investigated in an independent validation panel of 17 NMZL by targeted sequencing of tumor/normal DNA pairs (MiSeq; target region: 1.6 Mb; mean coverage per sample: 171x-386x). The 17 validation NMZL were also assessed for CNA by high resolution SNP arrays. RNAseq of 11 discovery NMZL did not identify any recurrent gene fusion. By compiling the results of WES and high resolution SNP array, 39 genes were recurrently affected in >3
  48. Structure of Janus kinase 2 with a pyrrolotriazine inhibitor PDB

    ID: PDB:3Q32

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  49. Transcription profiling of human CD4+ cutaneous T-cell lymphoma (CTCL) Sez-4 cell line activated with IL-2, IL-15 or IL-21 ArrayExpress

    ID: E-GEOD-8685

    Description: -regulated <40 genes. All three cytokines induced tyrosine phosphorylation of Jak1 and Jak3. However, only IL-2 and IL-15 strongly activated STAT5, PI3K/Akt, and MEK/ERK signaling pathways. In contrast, IL-21 selectively activated STAT3. Whereas all three cytokines protected CTCL cells from apoptosis, only IL-2 and IL-15 promoted their proliferation. The effects of the cytokine stimulation were Jak3- and Jak1-kinase dependent. These findings document the vastly different impact of IL-2 and IL-15 vs. IL-21 on malignant CD4+ T cells. They also suggest two n...

  50. Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness associated with a D... BioProject

    ID: PRJNA152007

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: ernal tandem duplication (ITD) of the fms-related tyrosine kinase-3 (FLT3) gene occurs in 30% acute myeloid leukemias (AML) and confers a poor pro...
  51. Gene expression of Kit225 cells upon NC1153 treatment ArrayExpress

    ID: E-GEOD-17007

    Description: NC1153 was shown to inhibit JAK3 tyrosine kinase. Lymphocytes survival depends on the integrity of STAT5, the primary dow...

  52. Gene expression profiling of Type II Enteropathy-associated T-cell lymphoma ArrayExpress

    ID: E-GEOD-70652

    Description: EATL samples that harbor mutations in the STAT5B, JAK3 and GNAI2 genes. Here we performed gene expression profiling on four Type II EATL samples in order to better characterize this disease. As Type II EATL is suggested to arise from CD8+ IELs, we integrated our data with publicly available profile of CD8αα and CD8αβ T-cells from healthy donors (GSE33374). Gene expression profiling independently demonstrated strong en...

  53. Comparison of the expression profiles of wild-type (WT), Tyk2-deficient (Tyk2-/-) and kinase-inactive Tyk2 mutant (Tyk2K923E) NK cells ArrayExpress

    ID: E-GEOD-68294

    Description: k2 and Tyk2K923E on the transcriptome of NK cells Tyrosine kinase 2 (TYK2) is a Janus kinase (JAK) that is crucially involved in...

  54. Interferon alpha induced gene expression in SOCS1 and SOCS3 overexpressing melanoma and hepatoma cell lines ArrayExpress

    ID: E-GEOD-22801

    Description: receptors by masking its recognition site for the Janus kinases (JAK), by blocking the kinase activity of the JAKs and coincidentally hindering STAT molecules from binding to the kinases. They are also thought to ubiquitinate the JAKs resulting in their proteosomal degradation. The function of SOCS proteins in suppressing the interferon-alpha pathway has not yet been characterized exhaustively. This study should unveil links to understand the resistance in interferon-alpha therapy. As results we got almost complete silencing of JAK-STAT signaling in SOCS1 over-expressing cells and tissue-dependent partially suppressed gene induction in SOCS3 over-expressing cell lines. Two human cancer cell lines (ME-15, HuH-7) were stably transfected with pcDNA3.1-SOCS plasmids in presence of geneticin and daughter cell lines were generated after singularization of cells. Next, original cell line...

  55. Activation of Sez-4 cell line with IL-2, IL-15 or IL-21. BioProject

    ID: PRJNA101899

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: -regulated <40 genes. All three cytokines induced tyrosine phosphorylation of Jak1 and Jak3. However, only IL-2 and IL-15 strongly activated STAT5, PI3K/Akt, and MEK/ERK signaling pathways. In contrast, IL-21 selectively activated STAT3. Whereas all three cytokines protected CTCL cells from apoptosis, only IL-2 and IL-15 promoted their proliferation. The effects of the cytokine stimulation were Jak3- and Jak1-kinase dependent. These findings document the vastly different impact of IL-2 and IL-15 vs. IL-21 on malignant CD4+ T cells. They also suggest two n...
  56. Methylation data and effect of JAK3 inhibition on human MO-to-DC and MO-to-MAC differentiation OmicsDI

    ID: E-GEOD-75937

    Date Released: 12-19-2015

    Description: ts on the methylation profiles of DCs and MACs of JAK3 inhibitor PF-956980 The methylation profiles of bisulfite-modified DNA of human CD14+ monocytes were compared with derived dendritic cells (DCs), macrophages (MACs) following GM-CSF/IL-4 and GM-CSF incubation, and DC and MAC samples incubated with JAK3 inhibitor PF-956980 using the Infinium HumanMethylation450 BeadChips (...

  57. Affymetrix Genome-Wide Human SNP Array 6.0 data for Type II Enteropathy-associated T-cell lymphoma ArrayExpress

    ID: E-GEOD-70653

    Description: EATL samples that harbor mutations in the STAT5B, JAK3 and GNAI2 genes. Genome-wide DNA copy number profiling of Type II EATL tumors and matched normal samples was performed to determine copy-number changes in this disease. Affymetrix SNP6 arrays were performed according to the manufacturer's directions on gDNA extracted from 4 tumors and 4 matched whole blood samples....

  58. Effect of a JAK inhibitor on gene expression of HUT78 cell line OmicsDI

    ID: E-GEOD-68562

    Date Released: 12-03-2015

    Description: increasing evidence that activating mutations in JAK genes and deregulated JAK/STAT signaling are important mechanisms involved in multiple B and T cell malignancies, including CTCL. Therefore, in this study we focused on studying the mutational status of JAK1, JAK2 and JAK3 genes in a series of human CTCL...

  59. Affymetrix Genome-Wide Human SNP Array 6.0 data for Type II Enteropathy-associated T-cell lymphoma BioProject

    ID: PRJNA289280

    Keywords: Variation

    Access Type: download

    dataset.description: EATL samples that harbor mutations in the STAT5B, JAK3 and GNAI2 genes. Genome-wide DNA copy number profiling of Type II EATL tumors and matched normal samples was performed to determine copy-number changes in this disease. Overall design: Affymetrix SNP6 arrays were performed according to the manufacturer's directions on gDNA extracted from 4 tumors and 4 matched whole blood samples....
  60. Effect of JAK1/3 blockade on IL2 response in NK cells OmicsDI

    ID: E-GEOD-84562

    Date Released: 07-23-2016

    Description: IL2 signals are transmitted through JAK1 and JAK3, but the transcriptomic consequences of each to the overall response is unclear. Here we analyzed the relative contribution of...

  61. Comparison of the expression profiles of wild-type (WT), Tyk2-deficient (Tyk2-/-) and kinase-inactive Tyk2 mutant (Tyk2K923E) NK cells BioProject

    ID: PRJNA282389

    Keywords: Transcriptome or Gene expression

    Access Type: download

  62. Interferon alpha induced gene expression in SOCS1 and SOCS3 overexpressing melanoma and hepatoma cell lines. BioProject

    ID: PRJNA127915

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: receptors by masking its recognition site for the Janus kinases (JAK), by blocking the kinase activity of the JAKs and coincidentally hindering STAT molecules from binding to the kinases. They are also thought to ubiquitinate the JAKs resulting in their proteosomal degradation. The function of SOCS proteins in suppressing the interferon-alpha pathway has not yet been characterized exhaustively. This study should unveil links to understand the resistance in interferon-alpha therapy. As results we got almost complete silencing of JAK-STAT signaling in SOCS1 over-expressing cells and tissue-dependent partially suppressed gene induction in SOCS3 over-expressing cell lines. Overall design: Two human cancer cell lines (ME-15, HuH-7) were stably transfected with pcDNA3.1-SOCS plasmids in presence of geneticin and daughter cell lines were generated after singularization of cells. Next, or...
  63. Gene expression profiling of Type II Enteropathy-associated T-cell lymphoma BioProject

    ID: PRJNA289281

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: EATL samples that harbor mutations in the STAT5B, JAK3 and GNAI2 genes. Here we performed gene expression profiling on four Type II EATL samples in order to better characterize this disease. As Type II EATL is suggested to arise from CD8+ IELs, we integrated our data with publicly available profile of CD8αα and CD8αβ T-cells from healthy donors (GSE33374). Gene expression profiling independently demonstrated strong en...
  64. Expression data from NKYS transfected with siRNAs or plasmids OmicsDI

    ID: E-GEOD-75680

    Date Released: 07-30-2016

    Description: The siRNA transfection includes JAK3 and EZH2 siRNAs. The plasmid transfection includes EZH2 WT and its mutants. We used gene expression data from JAK3

  65. Crystal structures of JAK1 and JAK2 inhibitor complexes PDB

    ID: PDB:3EYG

    Description: Tyrosine-protein kinase (E.C.2.7.10.2)

  66. PRJNA328967 BioProject

    Keywords: raw sequence reads

    Access Type: download

    dataset.description: ested grains constitute a major dietary source of protein for people in developing nations. Insect C1 cysteine protease inhibition and immune response is important in this plant(seed)-insect interaction. A reference transcriptome of 35,118 contigs was de novo assembled from a pooled cDNA library from all life stages sequenced by Roche 454 Titanium technology. Gene...
  67. Design and Synthesis of a pan-JAK kinase inhibitor clinical candidate (PF-06263276) suitable for the treatment of inflammatory diseases of the... PDB

    ID: PDB:5TQ3

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  68. Microarray analysis of TNFα indcued senescence in Human umbilical vein endothelial cells BioProject

    ID: PRJNA383932

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: feron signature, and persistent activation of the Janus kinase (JAK) /signal transducer and activator of transcription (STAT) pathway in TNFα-mediated senescence. TNFα initiates a STAT-dependent autocrine loop leading to sustained inflammation, DNA damage, and expression of interferon response genes to lock cells into senescence. Further, we show STAT1/3 activation is necessary for cytokine and ROS production during TNFα-induced senescence. However, inhibition of STAT1/3 did not rescue cells from TNFα-mediated senescence. Rather, blockade of STAT activation accelerated senescence, suppressed genes that control the cell cycle, and modulated TNFα-induced senescence. Our findings suggest a positive feedback mechanism via a STAT pathway that sustains cytokine production and reveal a reciprocal regulatory role of JAK/STAT in TNFα-mediated senescence. Overall design: Human umbilical vein endothelial cells (HUVECs) were untreated or treated TNFα (5ng/ml) co...
  69. miRNA Microarray analysis of TNFα induced senescence in Human umbilical vein endothelial cells BioProject

    ID: PRJNA358247

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: feron signature, and persistent activation of the Janus kinase (JAK) /signal transducer and activator of transcription (STAT) pathway in TNFα-mediated senescence. TNFα initiates a STAT-dependent autocrine loop leading to sustained inflammation, DNA damage, and expression of interferon response genes to lock cells into senescence. Further, we show STAT1/3 activation is necessary for cytokine and ROS production during TNFα-induced senescence. However, inhibition of STAT1/3 did not rescue cells from TNFα-mediated senescence. Rather, blockade of STAT activation accelerated senescence, suppressed genes that control the cell cycle, and modulated TNFα-induced senescence. Our findings suggest a positive feedback mechanism via a STAT pathway that sustains cytokine production and reveal a reciprocal regulatory role of JAK/STAT in TNFα-mediated senescence. Overall design: Human umbilical vein endothelial cells (HUVECs) were untreated or treated TNFα (5ng/ml) co...
  70. Discovery of novel recurrent mutations and rearrangements in early T-cell precursor acute lymphoblastic leukemia by whole genome sequencing ArrayExpress

    ID: E-GEOD-28703

    Description: signalling (67% of cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and BRAF); alterations disrupting haemopoietic development (58%; GATA3, ETV6, RUNX1, IKZF1, EP300); and inactivating mutations in histone modifying genes (48%; EZH2, EED, SUZ12, SETD2 and EP300). We also identified new targets of mutation including DNM2, ECT2L and RELN. Ten of 12 ETP ALL cases harboured chromosomal rearrangements, several of which complex and resulted in the expression of novel chimeric in-frame fusion genes disrupting haemopoietic regulators. Thus, similar to myeloid malignancies, mutations that drive proliferation, impair differentiation and disr...

  71. Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatmen... PDB

    ID: PDB:5TQ8

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  72. Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatmen... PDB

    ID: PDB:5TQ7

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  73. Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatmen... PDB

    ID: PDB:5TQ5

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  74. Activation of the JAK/STAT pathway in Behcet’s Disease BioProject

    ID: PRJNA261006

    Keywords: Transcriptome or Gene expression

    Access Type: download

  75. Crystal structures of JAK1 and JAK2 inhibitor complexes PDB

    ID: PDB:3FUP

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  76. Gene expression of Kit225 cells upon NC1153 treatment OmicsDI

    ID: E-GEOD-17007

    Date Released: 06-10-2011

    Description: NC1153 was shown to inhibit JAK3 tyrosine kinase. Lymphocytes survival depends on the integrity of STAT5, the primary dow...

  77. Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatmen... PDB

    ID: PDB:5TQ6

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  78. Design and Synthesis of a pan-JAK Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatmen... PDB

    ID: PDB:5TQ4

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  79. Gene expression profiling in erythroid progenitors through ontogeny OmicsDI

    ID: E-GEOD-37869

    Date Released: 05-03-2014

    Description: t has been reported that the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway regulates erythropoietin (EPO)-induced survival, proliferation, and maturation of early...

  80. Discovery of novel recurrent mutations and rearrangements in early T-cell precursor acute lymphoblastic leukaemia by whole genome sequencing ArrayExpress

    ID: E-GEOD-33315

    Description: including IL7R, NRAS, KRAS, FLT3, BRAF, JAK1 and JAK3 in ETP ALL. Moreover, we identified multiple new targets of mutation in including GATA3, EP300, RUNX1, DNM2, ECT2L, HNRNPA1 and HNRNPR, as well as genes known to be mutated in T-ALL, including NOTCH1, PHF6, and WT1.. Five of 12 ETP ALL cases harboured novel chromosomal translocations, several of which accompanied complex multichromosomal rearrangements and resulted in the expression of chimeric in-frame fusion genes disrupting hematopoietic regulators, including ETV6-INO80D, NAP1L1-MLLT10 and RUNX1-EVX1. These results indicate that although ETP ALL is genetically heterogeneous, activation of Ras and cytokine receptor signalling distinguishes this disease from non-ETP ALL....

  81. Discovery of novel recurrent mutations and rearrangements in early T-cell precursor acute lymphoblastic leukaemia by whole genome sequencing ArrayExpress

    ID: E-GEOD-28497

    Description: including IL7R, NRAS, KRAS, FLT3, BRAF, JAK1 and JAK3 in ETP ALL. Moreover, we identified multiple new targets of mutation in including GATA3, EP300, RUNX1, DNM2, ECT2L, HNRNPA1 and HNRNPR, as well as genes known to be mutated in T-ALL, including NOTCH1, PHF6, and WT1.. Five of 12 ETP ALL cases harboured novel chromosomal translocations, several of which accompanied complex multichromosomal rearrangements and resulted in the expression of chimeric in-frame fusion genes disrupting hematopoietic regulators, including ETV6-INO80D, NAP1L1-MLLT10 and RUNX1-EVX1. These results indicate that although ETP ALL is genetically heterogeneous, activation of Ras and cytokine receptor signalling distinguishes this disease from non-ETP ALL....

  82. Epigenetic Gene Regulation by Janus Kinase 1 in Diffuse Large B Cell Lymphoma (Agilent) BioProject

    ID: PRJNA341334

    Keywords: Transcriptome or Gene expression

    Access Type: download

  83. Gene expression profiling in erythroid progenitors through ontogeny ArrayExpress

    ID: E-GEOD-37869

    Description: t has been reported that the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway regulates erythropoietin (EPO)-induced survival, proliferation, and maturation of early...

  84. Sequencing of ETP T-ALL dbGaP

    ID: phs000340.v2.p1

    Description: signalling (67% of cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and BRAF), inactivating lesions disrupting haematopoietic development (58%; GATA3, ETV6, RUNX1, IKZF1 and EP300) and histone-modifying genes (48%; EZH2, EED, SUZ12, SETD2 and EP300). We also identified new targets of recurrent mutation including DNM2, ECT2L and RELN. The mutational spectrum is similar to myeloid tumours, and moreover, the global transcriptional profile of ETP ALL was similar to that of normal and myeloid leukaemia haematopoietic stem cells. These findings suggest that addition of myeloid-directed therapies might improve the poor outcome of ETP ALL....

  85. Transcription profiling of human Sez-4 cell line starved of IL2 for 16h, followed by addition of IL-2 activation and or JAK inhibition OmicsDI

    ID: E-GEOD-8687

    Date Released: 07-06-2011

    Description: -regulated <40 genes. All three cytokines induced tyrosine phosphorylation of Jak1 and Jak3. However, only IL-2 and IL-15 strongly activated STAT5, PI3K/Akt, and MEK/ERK signaling pathways. In contrast, IL-21 selectively activated STAT3. Whereas all three cytokines protected CTCL cells from apoptosis, only IL-2 and IL-15 promoted their proliferation. The effects of the cytokine stimulation were Jak3- and Jak1-kinase dependent. These findings document the vastly different impact of IL-2 and IL-15 vs. IL-21 on malignant CD4+ T cells. They also suggest two n...

  86. Sequencing of ETP T-ALL dbGaP

    ID: phs000340.v3.p1

    Description: signalling (67% of cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and BRAF), inactivating lesions disrupting haematopoietic development (58%; GATA3, ETV6, RUNX1, IKZF1 and EP300) and histone-modifying genes (48%; EZH2, EED, SUZ12, SETD2 and EP300). We also identified new targets of recurrent mutation including DNM2, ECT2L and RELN. The mutational spectrum is similar to myeloid tumours, and moreover, the global transcriptional profile of ETP ALL was similar to that of normal and myeloid leukaemia haematopoietic stem cells. These findings suggest that addition of myeloid-directed therapies might improve the poor outcome of ETP ALL....

  87. Fragment based discovery of JAK-2 inhibitors PDB

    ID: PDB:3E64

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  88. Fragment based discovery of JAK-2 inhibitors PDB

    ID: PDB:3E62

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  89. IL13_0-12h_RAIA_et_al ArrayExpress

    ID: E-GEOD-23591

    Description: (cHL) share a frequent constitutive activation of Janus-activated kinase (JAK) / signal transducer and activator of transcription (STAT) signaling pathway. Due to complex non-linear relations within the pathway, key d...

  90. Fragment based discovery of JAK-2 inhibitors PDB

    ID: PDB:3E63

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  91. Gene expression profiling in erythroid progenitors through ontogeny BioProject

    ID: PRJNA166911

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: t has been reported that the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway regulates erythropoietin (EPO)-induced survival, proliferation, and maturation of early...
  92. IL7R signaling mutations confer steroid resistance in T-ALL : IL-7 Receptor Mutations and Steroid Resistance in Pediatric T-Cell Acute Lymphoblastic L... BioProject

    ID: PRJEB11453

    Keywords: Other

    Access Type: download

    dataset.description: her genes in this pathway, including IL7Ra, JAK1, JAK3, NF1, NRAS, KRAS, and AKT, in these 69 T-ALL patients and an additional 77 T-ALL patients. We identified mutations in 32% of patients, the majority of whom had a specific T-ALL subtype (ETP-ALL or TLX). Based on the outcome of these patients and their prednisolone responsiveness measured in vitro, we then confirmed that these mutations are associated with both steroid resistance and poor outcome. To functionally explore how these mutations cause steroid resistance and subsequent poor outcome, we expressed wild-type and mutant IL7R signaling molecules in two steroid-sensitive T-ALL cell lines (SUPT1 and P12 Ichikawa cells) using inducible lentiviral expression constructs. We found that expressing mutant IL7Ra, JAK1, or NRAS, wild-type NRAS, or wild-type AKT specifically induced steroid resistance in both lines without affecting sensitivity to vincristine or asparaginase. In contrast, wild-type IL7R, JAK1, and JAK3, as well as mutant JAK3 and mutant AKT, had no effect. We then performed a functional study to examine the mechanisms underlying steroid resistance and found that resistance was not due to a change in the steroid receptor’s ability to activate downstream targets. Rather, steroid resistance was associated with strong activation of MEK-ERK and AKT, downstream components of IL7R signaling pathway, thereby inducing a robust anti-apoptotic response by upregulating MCL1 and BCL-XL expression. Both the MEK-ERK and AKT pathways also inactivate BIM, an essential molecule for steroid-induced death, and inhibi...
  93. Transcription profiling of human CD4+ cutaneous T-cell lymphoma (CTCL) Sez-4 cell line activated with IL-2, IL-15 or IL-21. OmicsDI

    ID: E-GEOD-8685

    Date Released: 06-10-2011

    Description: -regulated <40 genes. All three cytokines induced tyrosine phosphorylation of Jak1 and Jak3. However, only IL-2 and IL-15 strongly activated STAT5, PI3K/Akt, and MEK/ERK signaling pathways. In contrast, IL-21 selectively activated STAT3. Whereas all three cytokines protected CTCL cells from apoptosis, only IL-2 and IL-15 promoted their proliferation. The effects of the cytokine stimulation were Jak3- and Jak1-kinase dependent. These findings document the vastly different impact of IL-2 and IL-15 vs. IL-21 on malignant CD4+ T cells. They also suggest two n...

  94. Discovery of novel recurrent mutations and rearrangements in early T-cell precursor acute lymphoblastic leukemia by whole genome sequencing BioProject

    ID: PRJNA138921

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: signalling (67% of cases; NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3 and BRAF); alterations disrupting haemopoietic development (58%; GATA3, ETV6, RUNX1, IKZF1, EP300); and inactivating mutations in histone modifying genes (48%; EZH2, EED, SUZ12, SETD2 and EP300). We also identified new targets of mutation including DNM2, ECT2L and RELN. Ten of 12 ETP ALL cases harboured chromosomal rearrangements, several of which complex and resulted in the expression of novel chimeric in-frame fusion genes disrupting haemopoietic regulators. Thus, similar to myeloid malignancies, mutations that drive proliferation, impair differentiation and disr...
  95. Discovery of novel recurrent mutations and rearrangements in early T-cell precursor acute lymphoblastic leukaemia by whole genome sequencing BioProject

    ID: PRJNA149299

    Keywords: Transcriptome or Gene expression

    Access Type: download

    dataset.description: including IL7R, NRAS, KRAS, FLT3, BRAF, JAK1 and JAK3 in ETP ALL. Moreover, we identified multiple new targets of mutation in including GATA3, EP300, RUNX1, DNM2, ECT2L, HNRNPA1 and HNRNPR, as well as genes known to be mutated in T-ALL, including NOTCH1, PHF6, and WT1.. Five of 12 ETP ALL cases harboured novel chromosomal translocations, several of which accompanied complex multichromosomal rearrangements and resulted in the expression of chimeric in-frame fusion genes disrupting hematopoietic regulators, including ETV6-INO80D, NAP1L1-MLLT10 and RUNX1-EVX1. These results indicate that although ETP ALL is genetically heterogeneous, activation of Ras and cytokine receptor signalling distinguishes this disease from non-ETP ALL....
  96. CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] - PDB

    ID: PDB:5CF4

    Description: Tyrosine-protein kinase JAK2 (E.C.2.7.10.2)

  97. Expression data from Cerebral Cortex or Hippocampus of COX-1 or COX-2 null mice GEMMA

    ID: 374

    Keywords: functional genomics

    Description: BAergic neurotransmission genes (GABA transporter 3, GABA-A receptor subunit ?1) was altered in the cerebral cortex and hippocampus of COX-2 -/- mice. A COX isoform specific effect was observed in the expression of Janus Kinase (JAK) 1 and 2. COX-1 -/- mice exhibited an increase in JAK1 expression while COX-2 -/- mice exhibited a decrease in JAK2 expression, an observation consistent with a previously demonstrated COX isoform specific effect on the expression of NF-kB. In summary, this study demonstrates the wide ranging effects of genetic deletion of COX isoforms in the mouse brain and suggests that inhibition of COX activity may alter the profile of gene expression in specific areas of the brain. We u...

  98. onal and signalling characteristics of the fusion protein in human cancers... ArrayExpress

    ID: E-MTAB-2102

    Description: , we demonstrate that the oncogenic FIP1L1-PDGFRa kinase exhibits a significantly different signaling pattern compared to PDGFRa wildtype: Interestingly, the conventional strong activation of PI3-kinase- and MAP-kinase- pathways is remarkably shifted towards a prominent activation of STAT factors. This diverging signaling patte...

  99. Gene expression profiling upon knockdown of JAK1 in IM9 cells ArrayExpress

    ID: E-GEOD-37012

    Description: particular, gene silencing of two members of the JAK family (JAK1 and JAK2) in a variety of tumor cell targets increased their susceptibility to NK-mediated lysis and induced increased secretion of interferon gamma (IFN-gamma by NK cells. Treatment of tumor cells with JAK inhibitors also induced increased susceptibility to NK cell activity. These findings may have important clinical implications and suggest that small molecule inhibitors of tyrosine kinases being developed as therapeutic anti-tumor agents may also have significant immunologic effects in vivo. IM9 cells were transduced with shRNA-encoding vectors and selected with Puromycin. Two vectors were specifically targeting JAK1 (JAK1-1 and JAK1-3) and one vector encoded an irrelevant control shRNA (CTRL-2). T...

  100. Janus kinase 1 is essential for inflammatory cytokine signaling and mammary gland remodeling BioProject

    ID: PRJNA315865

    Keywords: Transcriptome or Gene expression

    Access Type: download


Displaying 100 of 559 results for "JAK3"